NeoGenomics is trading 4.3% up at $18.12 after CMS expanded Medicare coverage for its RaDaR ST molecular residual disease assay.
- The August 26, 2026, announcement expands coverage to monitoring responses to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.
- The decision builds on recent earnings momentum and supports optimism around broader reimbursement and commercial adoption.